Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Fabbro, Michel
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. [electronic resource] - Gynecologic oncology 03 2019 - 560-567 p. digital
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1095-6859
10.1016/j.ygyno.2018.12.009 doi
Adult
Aged
Aged, 80 and over
Female
Humans
Indazoles--adverse effects
Maintenance Chemotherapy
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Ovarian Neoplasms--drug therapy
Patient Reported Outcome Measures
Piperidines--adverse effects
Poly(ADP-ribose) Polymerase Inhibitors--adverse effects
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. [electronic resource] - Gynecologic oncology 03 2019 - 560-567 p. digital
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1095-6859
10.1016/j.ygyno.2018.12.009 doi
Adult
Aged
Aged, 80 and over
Female
Humans
Indazoles--adverse effects
Maintenance Chemotherapy
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Ovarian Neoplasms--drug therapy
Patient Reported Outcome Measures
Piperidines--adverse effects
Poly(ADP-ribose) Polymerase Inhibitors--adverse effects